Welcome to our dedicated page for CHINA PHARMA HOLDINGS SEC filings (Ticker: CPHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CHINA PHARMA HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CHINA PHARMA HOLDINGS's regulatory disclosures and financial reporting.
China Pharma Holdings, Inc. reported continuing losses and tight liquidity for the six months ended June 30, 2026. Revenue was $1.93 million, down 10.6% from $2.16 million a year earlier, but gross margin improved from a loss to a 19.1% profit margin as certain equipment became fully depreciated and inventory write-downs declined.
The company recorded a net loss of $2.60 million versus $1.31 million in the prior-year period, driven largely by higher amortization on newly acquired pharmaceutical patents. Cash and cash equivalents were only $0.30 million, and current liabilities exceeded current assets by $5.7 million. Management highlights a significant accumulated deficit of $49.8 million and relies on related-party loans, including $1.64 million advanced by the chairperson, to fund operations.
To expand its pipeline, the company issued 25,000,000 shares for intangible assets valued at $14.99 million, and subsequent to quarter-end raised $5.0 million gross (net $4.43 million) by selling 2,500,000 shares at $2.00 per share to an institutional investor. Intangible assets rose to $38.34 million, while Helpson’s operations remain concentrated in China and exposed to pricing pressure from national centralized procurement and evolving consistency-evaluation policies.
China Pharma Holdings, Inc. is conducting a primary offering of 2,500,000 shares of common stock at $2.00 per share under its $50,000,000 shelf registration. Gross proceeds are $5,000,000, with a 7% placement fee of $350,000 and estimated net proceeds of about $4.4 million.
Shares outstanding will increase from 40,522,002 to 43,022,002. The company intends to use the proceeds for working capital, supplementing operating cash flow and general corporate purposes. All operations are conducted through its PRC subsidiary Helpson, so investors face PRC legal, regulatory, capital‑controls and dividend‑remittance risks, as well as potential U.S. trading risks under the HFCAA if PCAOB inspections are impeded.
China Pharma Holdings, Inc. agreed on July 22, 2026 to sell 2,500,000 shares of common stock in a registered direct offering to an institutional accredited investor at $2.00 per share, for aggregate gross proceeds of $5,000,000, with closing expected on or around July 23, 2026.
The investor receives a right to participate in up to 40% of subsequent financings for three months after closing, while the company agrees for 91 days not to enter into subsequent placements or variable rate transactions, subject to exceptions. FT Global Capital, Inc. acts as exclusive placement agent and will receive a 7.0% cash commission on proceeds, plus a similar commission on qualifying financings with its contacted investors for 18 months after the placement agency agreement ends. The company plans to use net proceeds for working capital and general corporate purposes under an effective shelf registration statement (File No. 333-276481).
China Pharma Holdings reported Q1 2026 revenue of $0.98 million, down from $1.14 million a year earlier, as some key products faced weaker demand and competition from China’s centralized procurement system. The product mix shifted toward cardiovascular and cerebrovascular drugs, which became the largest revenue contributor.
The company posted a net loss of $1.14 million, wider than the $0.79 million loss in Q1 2025, mainly due to sharply higher amortization from recently acquired drug patents. Although gross margin improved to 29.0% from a prior gross loss, operating loss still reached $1.12 million.
Liquidity remains strained. Cash and cash equivalents were $0.17 million at March 31, 2026, and current liabilities exceeded current assets by $5.3 million. The CEO has advanced about $1.47 million in related-party loans, and management disclosed that these conditions create substantial doubt about the company’s ability to continue as a going concern.
During the quarter, China Pharma significantly expanded its intangible asset base by issuing 25,000,000 shares of common stock, valued at $15.0 million, to acquire two invention patents. This lifted total shares outstanding to 40,522,002 and increased stockholders’ equity but also materially diluted existing shareholders.
China Pharma Holdings, Inc. files its annual report for the year ended December 31, 2025, detailing a China-based generic and branded pharmaceutical business conducted through its wholly owned subsidiary Helpson. The company focuses on treatments for cardiovascular, central nervous system, infectious and digestive diseases, plus healthcare and protective products such as enzymes and masks.
China Pharma reports a negative gross margin of -3.2% in 2025, citing idle capacity, higher inventory impairment and lower product sales. Revenue is diversified across CNS, anti-infection, digestive and other categories, with anti-infection products the largest contributor. The filing emphasizes heavy exposure to PRC regulatory, pricing, medical insurance and procurement policies, as well as PCAOB inspection and HFCAA-related risks due to its U.S. listing.
China Pharma Holdings, Inc. submitted a Form 12b-25 notifying the SEC that its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 could not be filed on time and that the company intends to file the report no later than fifteen calendar days following the prescribed due date of March 31, 2026. Management provided preliminary estimates: revenue $4.1 million, cost of revenue ~$4.3 million, gross loss ~$0.1 million (gross loss margin ~3.2%), and net loss ~$3.19 million for 2025, and said fuller financial statements will appear in the Annual Report.
China Pharma Holdings, Inc. reported that its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd entered into a Technology Transfer Agreement on February 26, 2026 with Xiaoyan Zhang. The company will acquire an invention patent for Prinsepia Utilis Esterol sublingual tablets and related preparation methods.
As consideration, China Pharma agreed to pay $6.93 million in the form of its common stock at $0.55 per share, resulting in the planned issuance of 12,600,000 restricted shares of common stock. These shares will be issued to a non-U.S. person in an offshore transaction under Regulation S, and will not be registered under the U.S. Securities Act.
China Pharma Holdings, Inc. reported that its wholly owned subsidiary Hainan Helpson Medical & Biotechnology entered a Technology Transfer Agreement to acquire ownership of an invention patent for a Topiroxostat nanoemulsion and its preparation method from Xiaoyun Chen.
The transfer price is $8.82 million, to be paid in Company common stock at $0.70 per share, implying issuance of 12,600,000 restricted shares. Closing is expected by February 20, 2026. The shares will be issued in an offshore transaction to a non-U.S. person under Regulation S, without registration under the Securities Act.
China Pharma Holdings, Inc. reported results from its annual stockholders’ meeting for the fiscal year ended December 31, 2024. A total of 3,501,046 common shares, representing about 69.71% of outstanding shares as of the November 3, 2025 record date, were present in person or by proxy, providing a sufficient quorum.
Stockholders elected three independent directors—Gene Michael Bennett, Yingwen Zhang, and Baowen Dong—each receiving 3,500,416 to 3,500,418 votes for, with 628 to 630 votes withheld. Stockholders also approved an amendment to the Articles of Incorporation authorizing a reverse stock split at a ratio of up to 1-for-20 for the Company’s $0.001 par value common stock, with the Board retaining discretion over if and when to implement it. In addition, Amendment No. 3 to the Company’s Amended and Restated 2010 Long-Term Incentive Plan was approved, with 3,500,258 votes for, 774 against, and 14 abstentions.
China Pharma Holdings, Inc. reports that its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Agreement with Juan Zhang to acquire an invention patent covering Ipragliflozin tablets and their preparation method. The agreed transfer price is $9.8 million, to be paid in the company’s common stock at $1.40 per share.
To satisfy this consideration, the company is to issue 7,000,000 restricted shares of common stock. These shares will be offered and issued to a non-U.S. person in an offshore transaction relying on Regulation S, meaning they will not be registered under the U.S. Securities Act or state securities laws.